Sun Pharma receives US FDA nod for generic Gleevec
The company, being the first-to-file an ANDA for generic Gleevec (imatinib mesylate) with a para IV certification, is eligible for 180-days marketing exclusivity in the US
 "Sun Pharma receives US FDA nod for generic Gleevec")
As per IMS MAT August 2015, these tablets have annual sales of approximately $ 2.5 billion in the US. These tablets are indicated for the treatment of chronic myeloid leukemia.
The Sun Pharma subsidiary, being the first-to-file an ANDA for generic Gleevec with a para IV certification, is eligible for 180-days marketing exclusivity in the US. Under the terms of a settlement agreement with Novartis, the Sun Pharma subsidiary is permitted to launch its version of generic Gleevec in the US on February 1, 2016.